CL2018002754A1 - Proceso de produccion de raav a base de columnas completamente escalable. - Google Patents
Proceso de produccion de raav a base de columnas completamente escalable.Info
- Publication number
- CL2018002754A1 CL2018002754A1 CL2018002754A CL2018002754A CL2018002754A1 CL 2018002754 A1 CL2018002754 A1 CL 2018002754A1 CL 2018002754 A CL2018002754 A CL 2018002754A CL 2018002754 A CL2018002754 A CL 2018002754A CL 2018002754 A1 CL2018002754 A1 CL 2018002754A1
- Authority
- CL
- Chile
- Prior art keywords
- production process
- process based
- raav production
- fully scalable
- scalable columns
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Water Supply & Treatment (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316252P | 2016-03-31 | 2016-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002754A1 true CL2018002754A1 (es) | 2019-02-01 |
Family
ID=59966426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002754A CL2018002754A1 (es) | 2016-03-31 | 2018-09-27 | Proceso de produccion de raav a base de columnas completamente escalable. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11702639B2 (enExample) |
| EP (1) | EP3436051B1 (enExample) |
| JP (2) | JP7364306B2 (enExample) |
| KR (1) | KR102405250B1 (enExample) |
| CN (1) | CN109152821A (enExample) |
| AU (1) | AU2017240721B2 (enExample) |
| CA (1) | CA3019133A1 (enExample) |
| CL (1) | CL2018002754A1 (enExample) |
| CO (1) | CO2018011151A2 (enExample) |
| DK (1) | DK3436051T3 (enExample) |
| ES (1) | ES2896080T3 (enExample) |
| HU (1) | HUE056854T2 (enExample) |
| IL (1) | IL261970B2 (enExample) |
| LT (1) | LT3436051T (enExample) |
| MY (1) | MY195391A (enExample) |
| PE (1) | PE20190434A1 (enExample) |
| PH (1) | PH12018502104B1 (enExample) |
| PL (1) | PL3436051T3 (enExample) |
| PT (1) | PT3436051T (enExample) |
| RU (1) | RU2754467C2 (enExample) |
| SA (1) | SA518400146B1 (enExample) |
| SG (1) | SG11201808354PA (enExample) |
| WO (1) | WO2017173283A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| ES2896080T3 (es) * | 2016-03-31 | 2022-02-23 | Spark Therapeutics Inc | Procedimiento en columna totalmente escalable de preparación de VAAr |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| KR102877327B1 (ko) | 2016-08-29 | 2025-10-27 | 웨인 스테이트 유니버시티 | 개선된 광 민감성을 갖는 채널옵신 변이체에서의 돌연변이의 확인 및 이의 용도 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| SG11201913157RA (en) * | 2017-06-30 | 2020-01-30 | Spark Therapeutics Inc | Aav vector column purification methods |
| CN120505370A (zh) * | 2017-11-08 | 2025-08-19 | 诺华股份有限公司 | 制备病毒载体的手段和方法及其用途 |
| EP3784276A4 (en) * | 2018-04-24 | 2022-03-16 | Merck Sharp & Dohme Corp. | SCALABLE CHROMATOGRAPHY PROCEDURE FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| US12228571B2 (en) | 2018-06-08 | 2025-02-18 | Novartis Ag | Cell-based assay for measuring drug product potency |
| CN113383010B (zh) | 2018-09-28 | 2025-09-09 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
| US20220267796A1 (en) * | 2019-06-28 | 2022-08-25 | Takeda Pharmaceutical Company Limited | Adeno-associated virus purification methods |
| WO2021207132A1 (en) * | 2020-04-06 | 2021-10-14 | Brown University | Formulations and processes for treating water from impacted sources |
| JPWO2022045055A1 (enExample) * | 2020-08-24 | 2022-03-03 | ||
| US20230183659A1 (en) * | 2021-10-29 | 2023-06-15 | Homology Medicines, Inc. | Methods and compositions for the purification of adeno-associated virus |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5981716A (en) * | 1995-06-07 | 1999-11-09 | Gruppo Lepettit, S.P.A. | Process for the purification of proteins |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| DK1944362T3 (en) * | 1997-09-05 | 2016-01-25 | Genzyme Corp | Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer |
| AU2001257611A1 (en) | 2000-04-28 | 2001-11-12 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| US7261544B2 (en) * | 2003-05-21 | 2007-08-28 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
| HUE030719T2 (en) | 2007-04-09 | 2017-05-29 | Univ Florida | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
| KR101812813B1 (ko) * | 2009-06-16 | 2017-12-27 | 젠자임 코포레이션 | 재조합 ａａｖ 벡터에 대한 개선된 정제 방법 |
| EP2325194A1 (en) * | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| ES2680915T3 (es) * | 2010-01-28 | 2018-09-11 | The Children's Hospital Of Philadelphia | Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica |
| US20140248695A1 (en) | 2011-10-05 | 2014-09-04 | MolMed, S.p.A. | Viral Vectors Purification System |
| ES2896080T3 (es) | 2016-03-31 | 2022-02-23 | Spark Therapeutics Inc | Procedimiento en columna totalmente escalable de preparación de VAAr |
-
2017
- 2017-03-31 ES ES17776783T patent/ES2896080T3/es active Active
- 2017-03-31 HU HUE17776783A patent/HUE056854T2/hu unknown
- 2017-03-31 PE PE2018001938A patent/PE20190434A1/es unknown
- 2017-03-31 LT LTEPPCT/US2017/025396T patent/LT3436051T/lt unknown
- 2017-03-31 EP EP17776783.7A patent/EP3436051B1/en active Active
- 2017-03-31 SG SG11201808354PA patent/SG11201808354PA/en unknown
- 2017-03-31 PL PL17776783T patent/PL3436051T3/pl unknown
- 2017-03-31 KR KR1020187031464A patent/KR102405250B1/ko active Active
- 2017-03-31 CN CN201780022146.8A patent/CN109152821A/zh active Pending
- 2017-03-31 JP JP2018550782A patent/JP7364306B2/ja active Active
- 2017-03-31 WO PCT/US2017/025396 patent/WO2017173283A1/en not_active Ceased
- 2017-03-31 DK DK17776783.7T patent/DK3436051T3/da active
- 2017-03-31 IL IL261970A patent/IL261970B2/en unknown
- 2017-03-31 CA CA3019133A patent/CA3019133A1/en active Pending
- 2017-03-31 PH PH1/2018/502104A patent/PH12018502104B1/en unknown
- 2017-03-31 RU RU2018138164A patent/RU2754467C2/ru active
- 2017-03-31 US US16/088,743 patent/US11702639B2/en active Active
- 2017-03-31 AU AU2017240721A patent/AU2017240721B2/en active Active
- 2017-03-31 PT PT177767837T patent/PT3436051T/pt unknown
- 2017-03-31 MY MYPI2018001663A patent/MY195391A/en unknown
-
2018
- 2018-09-27 CL CL2018002754A patent/CL2018002754A1/es unknown
- 2018-09-30 SA SA518400146A patent/SA518400146B1/ar unknown
- 2018-10-18 CO CONC2018/0011151A patent/CO2018011151A2/es unknown
-
2022
- 2022-06-07 JP JP2022092235A patent/JP7659523B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018011151A2 (es) | Proceso de producción de raav a base de columnas completamente escalable | |
| CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
| MX2016009965A (es) | Produccion de alta titulacion de vectores virales adenoasociados. | |
| MX2019003489A (es) | Moleculas del receptor de envolvimiento quimerico. | |
| ECSP17042921A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
| DK3488007T3 (da) | Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved | |
| NZ725568A (en) | Modified j-chain | |
| MX375548B (es) | Manufactura de neurotoxinas de clostridium botulinum recombinantes. | |
| MX380263B (es) | Procesos para producir brivaracetam. | |
| MX2016011748A (es) | Anticuerpos humanizados con estabilidad incrementada. | |
| MX2021000153A (es) | Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos. | |
| CL2017000087A1 (es) | Un proceso novedoso para la purificación de rhu-gcsf | |
| MX378940B (es) | Trastornos neurodegenerativos. | |
| MX2017011976A (es) | Microorganismo recombinante para la produccion mejorada de quimicos finos. | |
| CO2018010286A2 (es) | Método para la purificación de proteínas | |
| MX2016014227A (es) | Estabilizante para procesos de produccion de poliol polimerico. | |
| MX2016014296A (es) | Proceso para preparar un poliol polimerico. | |
| CL2014002410A1 (es) | Método para la producción de proteínas recombinantes en glándula mamaria de mamíferos mediante la transformación del epítelio glandular mamario con vectores adenoasociados. | |
| EP3560989A4 (en) | FOAMING RESIN COMPOSITION, PROCESS FOR PREPARING THE SAME AND FOAM USING THE SAME | |
| BR102017019854A2 (pt) | dsba e dsbc ultrapurificados e métodos de produção e uso dos mesmos | |
| CR20170233A (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
| BR112018067897A2 (pt) | imunoglobulinas modificadas com ligação de fcrn alterada | |
| HK40003857A (en) | Column-based fully scalable raav manufacturing process | |
| UA103771U (ru) | Ректификационная колонна | |
| GB201514105D0 (en) | Cluster illumination by piezoelectric material |